GSK to cut 120 jobs at Aussie packaging plant; Servier, founder on trial in France for Mediator safety;

@FiercePharma: ICYMI: Does pharma spend more on marketing than R&D? A numbers check. Article | Follow @FiercePharma

@EricPFierce: Pfizer's effort to avoid a shortage after recall of new formulation of Levoxyl backfires with second recall. Article | Follow @EricPFierce

> GlaxoSmithKline ($GSK) plans to slice 120 jobs at a packaging plant in Melbourne, Australia as it revamps the facility to exit tablet packaging and focus on higher-tech ventures. Report

> Servier, which made the diabetes and weight loss drug Mediator, went on trial in France yesterday on charges that it and its founder, Jacques Servier, misled the public about the drug's safety; it has been linked with hundreds of deaths. Report

> European regulators approved HyQvia, from Baxter International ($BAX) and Halozyme Therapeutics ($HALO), to treat adults with primary and secondary immunodeficiencies. Report

> Children's pain relievers such as acetaminophen probably aren't causing new cases of asthma as feared, a study found. Report

> In the face of official recommendations against its Avastin cancer treatment in the U.K., Roche ($RHHBY) called on the country's government to clarify its policies on access to cancer drugs. Report

> A Novartis ($NVS) campaign in India known as Arogya Pariva, or "healthy family," won an award from GBCHealth, a coalition of organizations focused on public health. Report

Medical Device News

@FierceMedDev: If you missed it, here's FierceDrugDelivery's special report on the future of nanotech drug delivery. Feature | Follow @FierceMedDev

@MarkHFierce: Is the campaign to repeal the medical device industry tax "narrow-minded and dishonest?" More | Follow @MarkHFierce

 @DamianFierce: Terumo has prevailed in patent lawsuit against Vascular Solutions. Article | Follow @DamianFierce

> Boston Scientific, Elixir make waves at EuroPCR 2013. More

> Given Imaging envisions FDA sign-off by Q4 for PillCam Colon capsule. Story

> Johns Hopkins team views two genes as postpartum depression predictors. DxExtra

Biotech News

@FierceBiotech: PR: Life sciences industry vet Stephane Bancel joins Flagship Ventures. Release | Follow @FierceBiotech

@JohnCFierce: Is Novartis seriously scouting for new Alzheimer's drug candidates? More | Follow @JohnCFierce

@RyanMFierce: John Reynders is leaving AstraZeneca for CIO gig at hot biotech startup Moderna. Release | What he's done | Follow @RyanMFierce

> VC: Kineta, Omerix gain fresh venture backing for R&D programs. News

> GlaxoSmithKline wins up to $200M federal contract to develop new antibiotics. More

> Analysts tap the next big thing in biopharma R&D. Article

Drug Delivery News

@MichaelGFierce: Nanoparticles made from grapefruit lipids deliver drugs safely. More | Follow @MichaelGFierce

> Single-cell electroporation riddles cells with drug delivery holes. Article

> Elixir bolsters recent CE mark with successful pivotal trial. News

> Radioactive nanoparticles target, shrink metastasized lymphoma tumors. Story

> Alnylam records RNAi delivery success to treat rare disease. More

> FDA clears Oramed's oral insulin pill for PhII trials. Article

And Finally... Can treatment with statins counteract the beneficial effects of exercise? Report

Suggested Articles

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.